DeepMed Research

Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Gefitinib 250 mg
Drug: Lazertinib 240 mg/160 mg
Drug: Lazertinib-matching placebo 240 mg/160 mg
Drug: Gefitinib-matching placebo 250 mg

First Posted Date: 2020-01-30

Last Posted Date: 2024-12-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 393

Registration Number: NCT04248829

Locations: 🇵🇭
Perpetual Succour Hospital, Cebu, Philippines
🇹🇭
Prince of Songkla University, Hat Yai, Thailand
🇺🇦
Tsentralna miska klinichna likarnia, Úzhgorod, Zakarpats'ka Oblast', Ukraine

and more 77 locations

Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: YHP1903
Drug: Champix

First Posted Date: 2020-01-13

Last Posted Date: 2020-01-23

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 34

Registration Number: NCT04225052

Locations: 🇰🇷
Chonbuk national university hospital, Jeonju, Jeollabuk-do, Korea, Republic of

Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome

Phase 4

Completed

Conditions: Acute Coronary Syndrome
Carotid Atherosclerotic Plaque With Inflammation

Interventions: Drug: high-dose rosuvastatin
Drug: low-dose rosuvastatin plus ezetimibe

First Posted Date: 2019-08-14

Last Posted Date: 2019-08-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 50

Registration Number: NCT04056169

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia

Phase 4

Completed

Conditions: Dyslipidemias
Hypertension

Interventions: Drug: Amlodipine/Atorvastatin 5/20mg
Drug: Rosuampin 20/5mg
Drug: Rosuampin 10/5mg

First Posted Date: 2019-05-15

Last Posted Date: 2022-10-12

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 259

Registration Number: NCT03951207

Locations: 🇰🇷
Daegu Catholic Univ. Medical Center, Daegu, Korea, Republic of

Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients

Completed

Conditions: Ischemic Stroke

First Posted Date: 2019-01-30

Last Posted Date: 2022-10-12

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 1011

Registration Number: NCT03823274

Locations: 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of

Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg

First Posted Date: 2018-09-07

Last Posted Date: 2024-11-12

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 67

Registration Number: NCT03662620

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Jeollanam-do, Korea, Republic of

Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM

Phase 4

Completed

Conditions: Atherosclerotic Cardiovascular Disease
Type 2 Diabetes Mellitus

Interventions: Drug: Monorova
Drug: Rosuvamibe

First Posted Date: 2018-07-24

Last Posted Date: 2020-12-14

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 236

Registration Number: NCT03597412

Locations: 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: YH25448 240mg

First Posted Date: 2018-06-14

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 24

Registration Number: NCT03556436

Locations: 🇰🇷
Seoul National University Hospital Clinical Trial Center, Seoul, Korea, Republic of

HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

Phase 4

Conditions: Chronic Kidney Disease
Proteinuria

Interventions: Drug: Telmisartan 40mg
Drug: Telmisartan/Rosuvastatin 40/10mg

First Posted Date: 2018-06-08

Last Posted Date: 2020-12-14

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 374

Registration Number: NCT03550859

Locations: 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
🇰🇷
Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of

and more 13 locations

A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity

Phase 4

Completed

Conditions: Peripheral Artery Disease, PAD

Interventions: Drug: Anplag Tab. 100mg bid
Drug: Anplag Tab. 100mg tid

First Posted Date: 2018-04-26

Last Posted Date: 2020-06-23

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 60

Registration Number: NCT03509922

Locations: 🇰🇷
The Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Uijeongbu, Gyeonggido, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy